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 17 
Over few past years, “big data” has become a frequently used catchall phrase 18 
for research approaches involving the use of complex, large-scale data sets 1 2.  There 19 
are many types of data that may fit this description, but within the sphere of 20 
clinically-oriented research this term is often considered synonymous to Electronic 21 
Health Record (EHR) data, or Electronic Medical Record (EMR) data.  The powerful 22 
potential of these data for advancing biomedical research has been recognised by 23 
many 3-5. Funders in both the USA and the UK have recently made substantial 24 
investments in the area, such as the USD$215 million Precision Medicine Initiative 6 25 
announced by the US government and Genomics England, aiming to sequence 26 
100,000 whole genomes during routine clinical care7. Additionally, funding 27 
organizations are actively encouraging research utilizing large-scale biomedical data 28 
through specific initiatives. The Big Data To Knowledge (BD2K) programme8 was 29 
established by the National Institutes of Health (NIH) in 2012 to address the 30 
challenges and opportunities presented by big biomedical data through the provision 31 
of seed funding for  biomedical data-science based research, methods and training 32 
material development. In the UK, a consortium of 10 UK government and charity 33 
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funders, led by the Medical Research Council (MRC) have committed over £90 34 
million across several initiatives that are aimed at supporting translational research 35 
using big data such as the national Farr Institute of Health Informatics Research9, the 36 
UK Health Informatics Research Network (UKHIRN) and the Medical 37 
Bioinformatics Initiative. The amount of EHR data being digitally generated and 38 
collected is vast and rapidly expanding, and presents multiple opportunities that have 39 
the potential to transform medical practice and cardiovascular research across all 40 
stages of translation.   41 
 42 
However, big data is not a panacea for all research problems, and for many 43 
researchers the path from big data to clinical impact for a specific research question is 44 
unclear. There are many factors that must be considered when planning to use EHR 45 
data for research related not just to ethical and policy issues raised by combining data 46 
sources 10 11 but also the logistical and analytical decisions the process entails. One of 47 
the major impediments to the use of EHRs for research is that is the data they contain 48 
differs from data collected in a conventional cohort study or randomised controlled 49 
trial (RCT) in terms of both why and how it is recorded, and requires substantial 50 
processing before it can be statistically analysed.  These data are generated and 51 
recorded throughout the patient pathway during interactions with primary, secondary 52 
and tertiary healthcare providers.  Data from specialised disease registries, which 53 
were originally set up for auditing clinical standards and benchmarking quality 54 
improvement initiatives, may also be incorporated.  These different sources also 55 
record information in different ways.  EHR data can be structured (e.g. diagnosis 56 
recorded using medical classification systems such as the International Classification 57 
of Diseases 10th revision (ICD-10) 12 or SNOMED-CT13) or unstructured (e.g. textual 58 
narrative in clinical notes or coronary angiography reports in hospital information 59 
systems14). EHR are also increasingly including cardiovascular imaging data from 60 
procedures such as echocardiography, angiography, magnetic resonance imaging or 61 
computed tomography15. For all sources of information, data collection will have been 62 
motivated by clinical care, administrative, or other reasons, and will be recorded using 63 
a variety of ways.  The research-user is faced with substantial missing or incomplete 64 
information, data collected at irregular time-points, information that may be 65 
temporally inconsistent, and potentially the task of integrating and harmonising 66 
information contained in multiple sources.   67 
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These challenges are not insurmountable and do not mean that EHR data cannot be 68 
widely used for research, but do require a clear identification of research areas that 69 
can best leverage EHR data, and the development of tools that smooth the path from 70 
research question to research result. 71 
 72 
Research opportunities well-placed to leverage EHR data 73 
High-resolution observational cohort studies 74 
Linkage of multiple EHR data sources permits the creation of large-scale 75 
cohorts of patients for whom extensive follow-up data is already available. This 76 
allows researchers to answer questions that reliance upon traditional investigator-led 77 
cohort studies would otherwise make impossible due to the scale, diagnostic 78 
resolution, timeframe, or cost. In addition, it allows researchers to define and examine 79 
the entire patient journey, from early presentations of non-acute manifestations 80 
through the various syndrome transitions to cardiac (or non-cardiac) death. This 81 
enables them to resolve the time sequence, examine and understand, the aetiological 82 
and prognostic differences between different coronary disease phenotypes18.  83 
 84 
Chung et al. 19 were able to take advantage of available EHR data in this way 85 
to conduct a comparative effectiveness study of acute coronary care on an 86 
international scale.  Currently, Sweden and the UK are the only two countries in the 87 
world with ongoing, national registries for acute coronary syndrome events that cover 88 
all hospital care.  Using these data, the authors showed that 30-day mortality 89 
following acute myocardial infarction was substantially higher in the UK, and that 90 
uptake of effective treatment was slower in the UK.  The richness of the data meant 91 
that a substantial amount of clinical information could be incorporated into the 92 
casemix, including demography, risk factor comorbidity, and pre-hospital treatment.  93 
The researchers were also able to determine that diagnoses made in the two countries 94 
were comparable by examining troponin values and propensity to make a diagnosis.  95 
The results from this study are thus more robust than those based on a simple 96 
comparison of mortality rates, or focused on data from bespoke studies undertaken in 97 
hospitals that may not be representative of the broader healthcare system. 98 
 99 
EHR cohorts can also be used to make timely contributions to debates of 100 
clinical importance, such as the controversy over the relationship between varenicline 101 
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and adverse cardiovascular events. In 2011 a meta-analysis of 14 RCTs raised 102 
concerns that use of varenicline for smoking cessation may increase risk for adverse 103 
cardiovascular events (ischemia, arrhythmia, congestive heart failure, sudden death or 104 
cardiovascular-related death)20.  Three subsequent meta-analyses of RCTs did not find 105 
a significant association21-23.  However, the question remains controversial, partly due 106 
to disagreements over analytical methods used in these studies, but also because meta-107 
analyses are limited to the analysis of existing studies22 24 25. Svanström and 108 
colleagues were able to rapidly contribute new data to the debate by investigating the 109 
question in a cohort made up of the EHR data of over 35,000 Danish individuals who 110 
used either varenicline or bupropion for smoking cessation 26.  In this observational 111 
study, published in 2012, there was no evidence for a higher number of adverse 112 
events in patients using varenicline (acute coronary syndrome, ischaemic stroke, and 113 
cardiovascular death).  It would not have been feasible to take a comparable 114 
traditional cohort study from study design to publication within a similar timeframe, 115 
especially as very large number of patients would be required to ensure sufficient 116 
outcome numbers (only 117 were observed amongst the 35,000 patients in the EHR 117 
study). 118 
 119 
The capacity to investigate novel research questions has generally been 120 
limited by available data and funding for obtaining new data, but EHR data can 121 
potentially be used to address this problem.  The relationship between auto-immune 122 
inflammatory conditions and atrial fibrillation is one example where EHR data have 123 
been able to fill a research niche.  Although there is substantial research interest in 124 
this area 27, many of the large cardiovascular cohort studies (e.g. Framingham28) have 125 
limited data available on inflammatory conditions as this was not part of the original 126 
study design.  However, researchers in the UK, USA, and Denmark have been able to 127 
use EHR resources to explore this research area using very large samples, finding 128 
associations with increased risk of AF and a range of conditions including rheumatoid 129 
arthritis and psoriasis29-32.  Other researchers have taken an even broader, non-130 
hypothesis-driven approach, using advanced computation techniques that consider 131 
any and all disease information available in EHR data to identify novel associations 132 
between diseases 33.  The costs associated with using EHR data for these studies 133 
would have been much lower than comparable data-collection, making them a cost-134 
effective entry point into new areas of cardiovascular research. 135 
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 136 
Enhanced clinical trials 137 
There is growing concern that current model of discovering new interventions, 138 
evaluating them through clinical trials and implementing the findings as part of 139 
clinical care is significantly inefficient. The translation process itself is taking too 140 
long, with an average figure of 17 years reported in some cases34. Additionally, the 141 
number of new drugs introduced to the market pet year has been broadly flat since the 142 
1950s yet the costs have steadily grown35 and the cost of bringing a new licensed drug 143 
to the market has been estimated between 5 and 11 billion USD$36.  144 
 145 
In cardiovascular diseases, the problem is more acutely manifested through 146 
problems observed in the current clinical trials pipeline. There is a lack of 147 
contemporary and representative population data that can be utilized to draw accurate 148 
estimates of events and inform the selection of appropriate primary and secondary 149 
endpoints for clinical trial. Clinical trials are often conducted in highly selected 150 
populations that are not necessarily representative of the populations presented in 151 
routine clinical care and as such, results obtained have limited generalizability and 152 
external validity37. For example, the clinical characteristics, treatments and inpatient 153 
outcomes of patients enrolled in a large trial of acute heart failure (Acute Study of 154 
Nesiritide in Decompensated Heart Failure) were found to be significantly different 155 
that those found in a contemporary disease registry38. Furthermore, despite their 156 
growing importance in CVD research, non-drug interventions such as interventions 157 
based on clinical algorithms and decision support tools are not systematically 158 
evaluated through clinical trials since the process of randomization and outcome 159 
ascertainment is not seamlessly integrated into the clinical care pathway.  160 
 161 
This has had a significant negative impact on clinical trial conduct and 162 
findings. For example, recently there have been several late drug failures occurring 163 
within phase III clinical trials of therapeutic agents each costing several hundred 164 
million USD$.  High-Density Lipoprotein Cholesterol (HDL-C) raising agents such as 165 
niacin, fibrates and cholesteryl ester transfer protein (CETP) failed to reduce all cause 166 
mortality, coronary heart disease mortality and myocardial infarction event rates in 167 
patients treated with statins39. Likewise, heart rate lowering agents such as ivabradine 168 
when introduced to patients with stable coronary artery disease without clinical heart 169 
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failure failed to improve cardiovascular mortality and non-fatal myocardial infarctions 170 
rates 40. 171 
 172 
There is growing optimism that EHR can enrich RCT design, delivery and 173 
follow up.. EHR data can offer real-world phenotype-rich data that can directly 174 
inform trial design, enable the identification of optimal target populations and offer 175 
accurate event rate estimates similar to those encountered in clinical care. The entire 176 
trial conduct pipeline, from recruitment at the point of care to randomization and 177 
adverse event capture can be integrated with routine clinical care enabling the cost-178 
effective and efficient trialling of non-drug interventions. Additionally, EHR can 179 
provide richer contemporary data on trial participants at a fraction of the cost thus 180 
enabling the generalization of trial results to external populations 41. For example, the 181 
Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction (TASTE) 182 
trial42 for assessing the clinical effect of routine intracoronary thrombus aspiration 183 
before primary percutaneous coronary intervention in patients with ST-segment 184 
elevation myocardial infarction recruited patients by enrolling patients though the 185 
Swedish Coronary Angiography and Angioplasty Registry and utilizing national EHR 186 
and registry data for defining trial endpoints. Finally, EHR data provide valid, 187 
complete, long-term follow-up of phase III trials that would otherwise be too costly 188 
and complex to establish and too narrow in focus 43. While EHR offer a rich data-189 
scaffolding for designing and implementing clinical trials, significant challenges still 190 
exist, mainly around information governance and recruitment of clinicians as outlined 191 
in the evaluation by van Staa and colleagues44 45.  192 
 193 
Challenges in the pathway from EHR data to research results 194 
 195 
Although the benefits of using EHR data for research are potentially large, the 196 
widespread use of EHR data is hampered by the fact that there are currently a number 197 
of additional steps, and many associated queries, in the pathway from research 198 
question to results and publication.  As an example, consider a research project using 199 
existing data to investigate whether there is a relationship between gender and onset 200 
of atrial fibrillation (AF).  Most projects would involve applying standard analytical 201 
techniques to a bespoke investigator-led cohort of healthy individuals followed-up for 202 
cardiovascular conditions including AF (e.g. The Framingham Heart Study).  For an 203 
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existing data set, only relatively minimal data preparation would be required before 204 
analyses could be conducted and data are often provided with detailed documentation.  205 
However, using existing EHR data to answer the same question would require a 206 
number of additional preparatory steps before statistical analyses could be conducted.  207 
Broadly speaking, these relate to: (i) identifying the EHR source(s) that contain the 208 
data needed for the research question; (ii) developing strategies for extracting the 209 
required information from the data source(s), and combining it where necessary; (iii) 210 
creating a data set that is ready for analysis using standard statistical techniques (see 211 
Figure 1). 212 
 213 
 214 
Figure 1: Diagram of steps from research question to results and publication.  The four central circles show 215 
the path from research question to results for a conventional study using existing data.  Circles on outside of 216 
the spiral indicate the additional steps needed to conduct a research project using electronic health record 217 
data. 218 
 219 
What EHR data sources are available? 220 
8 
The availability of diverse data sources, including EHR, is rapidly expanding, 221 
making the identification of relevant sources for a single project overwhelming.  222 
Selecting appropriate data sources for research is dependent upon knowledge of the 223 
patients included (e.g. in-patients, ambulatory care, specialist treatment), the types of 224 
data recorded (e.g. diagnosis, prescriptions, test results, procedures), and the format of 225 
those data (e.g. diagnostic codes, imaging, free text), but often much of this can be 226 
difficult to determine in detail until data access has been granted.  A recent Wellcome 227 
Trust report on the discoverability of EHR and other biomedical datasets for 228 
research46 found that for the vast majority of sources, no systematic method is used to 229 
capture, curate, and display information about the data contained in each source, or to 230 
provide guidance on the information governance restrictions attached to them which 231 
determine how they can be accessed and used for research.  The limited use of 232 
standardised methods (e.g. metadata) for describing such information hinders 233 
recognition of the limitations and opportunities these data sources present, and 234 
potentially results in under-utilisation of data sources due to lack of knowledge about 235 
what they contain.   236 
 237 
However, overcoming this challenge is worth the additional effort, as 238 
combining data from multiple sources strengthens EHR-based cardiovascular 239 
research.  For example, Herrett et al. explored the completeness of recording for acute 240 
myocardial infarction (AMI) in four EHR sources: primary care (Clinical Practice 241 
Research Datalink; CPRD), hospital admissions (Hospital Episode Statistics; HES); a 242 
MI disease registry (Myocardial Ischaemia National Audit Project; MINAP), and 243 
national mortality data (Office of National Statistics; ONS).  Compared to the disease 244 
registry, which was treated as the gold standard data source, none of the other data 245 
sources captured all MI events and consequently incidence rates based on data from a 246 
single source were underestimated by 25-50% 47. This finding is not limited to AMI; a 247 
similar investigation of AF diagnoses found that only about 40% of the 72,793 AF 248 
patients identified had a diagnosis recorded in both primary and secondary care 48.   249 
 250 
Thus, for our example research question regarding gender and AF, we would 251 
likely decide to combine multiple EHR data sources, such as CPRD, HES, and ONS.  252 
This would enable us to use a sample of individuals broadly representative of the UK 253 
general population, and would include a more representative set of AF cases as 254 
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diagnoses made in both primary and secondary care would be identified.  However, 255 
individual access applications would need to be made for each EHR source prior to 256 
linkage of the different data sources, and information about what is contained within 257 
each would currently be limited to knowledge of the clinical coding systems used. 258 
 259 
How can I define clinical conditions in EHR data? 260 
Once relevant the data source(s) have been identified, researchers face another 261 
challenge: how to determine which patients have been diagnosed with a particular 262 
condition.  Extracting phenotypic information (i.e. disease status), a process known as 263 
phenotyping, is a time-consuming and challenging task even in relation to a single 264 
data source, as multiple diagnosis codes may be used to describe similar or related 265 
conditions and their data.  This challenge is amplified when data from multiple 266 
sources, recorded using different coding systems, are combined.  Figure 2 illustrates 267 
this, using as an example data for one individual from the three EHR sources in our 268 
hypothetical research question.  In this example, an AF diagnosis is recorded at three 269 
different time-points: as a secondary diagnosis during a hospital admission, in the 270 
primary care record after hospital admission information is transferred to their GP, 271 
and as a primary diagnosis when the patient is admitted to hospital for an AF-related 272 
surgical procedure.  This information needs to be reconciled in order to determine not 273 
only if, but also when, a diagnosis occurred.   274 
 275 
 276 
Figure 2: Illustration of linked primary care data (Clinical Practice Research Datalink; CPRD), secondary 277 
care data (Hospital Episode Statistics; HES), and mortality data (Office of National Statistics; ONS) for a 278 
single patient.  Circles on the top line show events recorded in one or more sources; red circles indicate a 279 
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diagnosis.  DVT indicates deep vein thrombosis; INR indicates International Normalisation Ratio; AF 280 
indicates atrial fibrillation; HF indicates heart failure. 281 
 282 
Reconciling coded information from multiple sources is made more 283 
challenging by the different medical classification systems that are used by each 284 
source.  For example, in the UK, primary care sources use Read codes, a subset of the 285 
Systematic Nomenclature of Medicine – Clinical Terms (SNOMED-CT) clinical 286 
terminology, whereas secondary care and mortality sources use the International 287 
Classification of Disease – 10th Revision (ICD-10).  Combining data recorded using 288 
these systems for a single condition, such as AF, is not straightforward as the clinical 289 
resolution they offer can vary substantially; there are 23 Read codes relating to AF, 290 
including disease subtype classification, but only one ICD-10 code. Data-driven 291 
computational methodologies, such as support vector machines (SVM), can be 292 
applied on unstructured data (e.g. clinical text, electrocardiographic (ECG) 293 
monitoring data) to further enhance and fine-tune the accuracy of algorithms utilizing 294 
coded data 4 49 50.  For example, Mohebbi et al. created an algorithm which consistsed 295 
of a linear discriminant analysis based feature reduction scheme and a SVM-based 296 
classifier and were able to accurately (sensitivity 99.07%, specificity 100%, positive 297 
predictive value 100%) detect AF cases using RR intervals extracted from ECG 298 
signals51. 299 
 300 
No standardised methodologies and mechanisms exist to help research-users 301 
define, share and evaluate EHR-derived phenotypes in a consistent way, or to apply 302 
algorithms for creating these phenotypes to their own data, although development of 303 
tools for this is very active 52-54.  The USA-based eMERGE Consortium have 304 
developed an AF phenotype algorithm 55 which focuses on clinical notes and 305 
electrocardiogram impression data.  These data are not available in CPRD, HES, or 306 
ONS, although there is a UK-oriented EHR phenotype resource called CALIBER that 307 
does contain an AF phenotype based on coded data from primary and secondary care 308 
48, which could be applied in this situation.  However, if no phenotype algorithm 309 
existed, we would need to go through the process of developing a new phenotype 310 
algorithm for AF, and we would need to repeat this process for every other variable 311 
we wanted to include in our final data set such as gender and any covariates such as 312 
other cardiovascular diseases, smoking status, or hypertension. 313 
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 314 
Validation, preferably against a gold standard, is a key step of defining disease 315 
phenotyping algorithms56. The goal of the validation exercise is to evaluate the 316 
accuracy of the algorithm: is the phenotyping algorithm including all patients that are 317 
eligible and excluding all patients that are ineligible, thus accurately allocating them 318 
in the case and control groups. Some phenotypes, such as type 2 diabetes57, are 319 
inherently complex as they make use of multiple data elements (e.g. diagnostic codes, 320 
medication information, laboratory measurements, clinical text) and should ideally be 321 
validated through manual review of case notes in primary or secondary healthcare 322 
providers in order to understand the information the physician had available at the 323 
time of diagnosis. Clinical notes however are not available at scale due to information 324 
governance restrictions and scaling this process for large cohorts of patients is 325 
challenging and time-consuming. An alternative approach is to validate the developed 326 
phenotyping algorithms by conducting epidemiological analyses of the association of 327 
known risk factors and the phenotype in question and compare associations found in 328 
other studies. Other phenotypes, such as white blood cell count, the goal of the 329 
validation exercise is to ensure that the algorithm included all eligible patients and 330 
discarded outliers and incorrect values.  331 
 332 
How do I create a research-ready EHR data set? 333 
The process of applying phenotype algorithms to raw EHR data and creating a 334 
data set that is ready to be statistically analysed requires several data transformations 335 
that are challenging due to data heterogeneity and complexity.  Description of the 336 
process is rarely provided as part of academic outputs, and there is increasing 337 
recognition of the weaknesses that pervade the current landscape of EHR research in 338 
relation to sharing and standardisation of data transformation methods 58. The 339 
prevalent scientific culture does not promote or reward sharing of standardised and re-340 
usable data transformation libraries, which leads to substantial duplication of effort 341 
and increases the potential for a lack of reproducible results from EHR-based studies.  342 
 343 
As for a conventional study, an EHR-based study requires a clear definition 344 
including the population from which individuals are sampled, inclusion and exclusion 345 
criteria, follow-up, and handling of missing data.  For our example question, we may 346 
need to specify the age range of our patients, whether we are including individuals 347 
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with prior cardiovascular conditions such as heart failure, and how missing data were 348 
handled, but there is additional information that should be reported for EHR data 349 
including: the data sources included, the end date of our follow-up data, whether there 350 
are exclusion/inclusion criteria based on data quality or other administrative 351 
information, details of new phenotype algorithms, and how data were multiply 352 
imputed if applicable.  While this information can be described to some extent in the 353 
Methods section of a scientific paper, the associated computational manipulation and 354 
analyses are not standardised for EHR data, and there is currently no provision in 355 
scientific papers for detailed explanations of these methods or distribution of 356 
associated phenotype algorithms, computer software, or scripts.   357 
 358 
Recommendations for advancing EHR research 359 
 360 
Many countries in Europe, and internationally, have EHR systems that could 361 
be utilised for research; national, centralised resources that facilitate the steps from 362 
research question to research data set would substantially enhance the research 363 
potential of these data sources.  Initiatives are already underway to achieve this in 364 
some countries, but few tackle all aspects of this process.  365 
 366 
The UK-based CALIBER platform 59 combines a repository of EHR 367 
phenotypes with curated record linkages combining primary care (Clinical Practice 368 
Research Datalink), hospital discharge (Hospital Episode Statistics), disease registry 369 
(Myocardial Ischaemia National Audit Project60) and death registry (Office of 370 
National Statistics) data in over 2 million adults with 10 million person years of 371 
follow-up.  However, this resource does not provide any tools for bidirectional 372 
interactions with EHR data sources.  In contrast, the Clinical Record Interactive 373 
Search (CRIS) system (based at the NIHR Mental Health Biomedical Research Centre 374 
and Dementia Unit at the South London and Maudsley NHS Foundation Trust) allows 375 
researchers to investigate anonymised secondary care data, including clinical notes 376 
and other text, via novel user-friendly tools that facilitate identification of patients 377 
meeting certain criteria and development of text-mining algorithms 61.  The Electronic 378 
Medical Records and Genomics (eMERGE) Network 52, a US National Human 379 
Genome Research Institute-funded consortium, combines a phenotype repository with 380 
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EHR data from multiple secondary healthcare providers, including imaging and text, 381 
linked to genotypic data for all participants.    382 
 383 
National EHR portals could combine the strengths of all these projects by 384 
including: (i) a national catalogue of contemporary EHR sources curated using 385 
metadata standards; (ii) an interactive thesaurus of EHR-derived phenotype 386 
algorithms; (iii) standards-driven tools that will enable researchers to visually create 387 
observational and interventional research studies (population, inclusion/exclusion 388 
criteria, sources, phenotypes).  The national catalogue should support the harvesting 389 
and integration of metadata from external sources, and manual curation by researchers 390 
within a standardised and reproducible framework, as well as providing guidance on 391 
data access and data content.  This will allow users to identify data sources that can 392 
provide information both within and across disease areas. The EHR phenotype 393 
algorithms and data set creation tools need to be implemented in a fashion that 394 
supports reuse and modification by other users, as well as appropriate academic credit 395 
and/or citation.  Creating this type of resource will help to foster an "open source" 396 
approach to EHR research in which researchers can collaborate and learn from each 397 
other, and this will ultimately produce a greater advance in EHR research than could 398 






Electronic Health Records: Electronic Health Records (EHR) are data generated and 405 
recorded during routine clinical care. EHRs are diverse and encompass nationally and 406 
regionally available structured and unstructured data from primary care, hospitals, 407 
administrative data, and disease, procedure and death registries; increasingly 408 
including genomic, imaging and patient sensor data. 409 
Medical ontology: a structured controlled vocabulary of medical concepts and their 410 
semantic relations used to record, store and transmit medical knowledge and patient-411 
related clinical information efficiently 412 
14 
Metadata: is data that describes aspects around a particular data element. For an EHR 413 
source metadata can include information about the manner in which the data get 414 
generated and recorded, the medical ontologies used to record information and the 415 
methods by which researchers can access the data for research. 416 
Phenotyping: In the context of EHR, phenotyping is defined as the process of 417 
creating algorithms that define an observable trait (physical or biochemical) such as a 418 
clinical condition within EHR data. 419 
Box 1. Definitions 420 
 421 
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